ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Erectile dysfunction: a global review of intracavernosal injectables
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 142847" data-attributes="member: 13851"><p><strong>Abstract </strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Purpose </strong></span>Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Methods</span></strong> A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluate clinical efficacy, continuation rates and adverse event profiles of each injectable agent as monotherapy or in combination. The secondary outcome measurement was to discuss available guidelines that inform clinical practice for injectable agents. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results </span></strong>ICIs demonstrate clinical efficacy in 54–100% of patients, early discontinuation rates of ≤38% and adverse events in ≤26%. Discontinuation rates are typically greatest within 3–6 months of commencement. Anxiety related to the initial injection occurs in approximately 65% and anxiety levels can remain high for 4 months. Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. Although combination therapies are attractive alternative options, their formulations are variable and should be standardised before widespread acceptance is achieved. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Conclusions</span></strong> ICIs are associated with good clinical efficacy rates, high discontinuation rates and a moderate side-effect profile. They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies. </p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion </strong></p><p><strong><span style="color: rgb(184, 49, 47)">ICIs are associated with good clinical efficacy rates, high discontinuation rates and a significant side-effect profile.</span></strong> <strong>They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies.</strong> Their primary role appears to be as a second-line therapy in motivated and well-counselled male patients and for penile rehabilitation in male patients after pelvic surgery. <strong><span style="color: rgb(184, 49, 47)">Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. </span></strong>Although combination therapies are attractive alternative options in patients with an adverse response to alprostadil alone, their formulations are variable and should be standardised before widespread acceptance can be achieved.</p></blockquote><p></p>
[QUOTE="madman, post: 142847, member: 13851"] [B]Abstract [/B] [COLOR=rgb(184, 49, 47)][B]Purpose [/B][/COLOR]Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice. [B][COLOR=rgb(184, 49, 47)]Methods[/COLOR][/B] A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluate clinical efficacy, continuation rates and adverse event profiles of each injectable agent as monotherapy or in combination. The secondary outcome measurement was to discuss available guidelines that inform clinical practice for injectable agents. [B][COLOR=rgb(184, 49, 47)]Results [/COLOR][/B]ICIs demonstrate clinical efficacy in 54–100% of patients, early discontinuation rates of ≤38% and adverse events in ≤26%. Discontinuation rates are typically greatest within 3–6 months of commencement. Anxiety related to the initial injection occurs in approximately 65% and anxiety levels can remain high for 4 months. Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. Although combination therapies are attractive alternative options, their formulations are variable and should be standardised before widespread acceptance is achieved. [B][COLOR=rgb(184, 49, 47)]Conclusions[/COLOR][/B] ICIs are associated with good clinical efficacy rates, high discontinuation rates and a moderate side-effect profile. They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies. [B]Conclusion [COLOR=rgb(184, 49, 47)]ICIs are associated with good clinical efficacy rates, high discontinuation rates and a significant side-effect profile.[/COLOR][/B] [B]They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies.[/B] Their primary role appears to be as a second-line therapy in motivated and well-counselled male patients and for penile rehabilitation in male patients after pelvic surgery. [B][COLOR=rgb(184, 49, 47)]Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. [/COLOR][/B]Although combination therapies are attractive alternative options in patients with an adverse response to alprostadil alone, their formulations are variable and should be standardised before widespread acceptance can be achieved. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Erectile dysfunction: a global review of intracavernosal injectables
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top